Leave a Reply
You must be
to post a comment.
Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica
Dr. Gregory Fiore to Participate in a Panel on Pain Management: Alternatives to Opioids at BioOhio’s Neuroscience Discovery & Alternatives to Opioids Event
Ohio State neurosurgeon’s startup could seek Third Frontier funds to reduce opioid prescriptions
State awards money to support technological solutions to fight opiates
Neurotechnology Innovations Translator (NIT) Announces Funding of up to $50 Million in Portfolio Company Sollis Therapeutics